Breaking News

Sekisui Invests $1.9M in Microbial Biopharma CDMO Business

New BioProcess Innovation Center in UK will be operational by the end of 2019

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sekisui Diagnostics’ Enzyme business will complete a new BioProcess Innovation Center in Maidstone, Kent by the end of 2019, following a $1.9 million investment. This investment is part of a long-term investment strategy to grow its share of the microbial biopharma CDMO market, with future investment expected to focus on expanding cGMP manufacturing capabilities.   Previously part of Genzyme Diagnostics, Sekisui Diagnostics’ Enzyme business launched its microbial biopharma CDMO service off...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters